Company Description
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines.
The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.
The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
| Country | United States |
| Founded | 1982 |
| IPO Date | Mar 5, 1985 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Stacy Lindborg |
Contact Details
Address: 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 United States | |
| Phone | 609 896 9100 |
| Website | imunon.com |
Stock Details
| Ticker Symbol | IMNN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000749647 |
| ISIN Number | US15117N6022 |
| Employer ID | 52-1256615 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stacy R. Lindborg Ph.D. | President, Chief Executive Officer and Director |
| Michael H. Tardugno | Executive Chairman |
| Timothy J. Tumminello CPA | Chief Accounting Officer and Controller |
| Susan Mary Eylward | General Counsel and Corporate Secretary |
| Kristin Longobardi M.B.A. | Senior Vice President of Strategic Operations |
| Dr. Douglas V. Faller M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2025 | EFFECT | Notice of Effectiveness |
| Jun 13, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 424B3 | Prospectus |
| Jun 11, 2025 | ARS | Filing |
| Jun 9, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 9, 2025 | 8-K | Current Report |
| May 30, 2025 | SCHEDULE 13G | Filing |
| May 30, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 30, 2025 | PRE 14A | Other preliminary proxy statements |
| May 30, 2025 | 8-K | Current Report |